



## Altimune to Participate at Two Upcoming Investor Conferences

May 7, 2024 at 7:30 AM EDT

GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

- **JMP Life Sciences Conference** (New York, NY)  
Tuesday, May 14, 2024  
*Fireside Chat at 9:00 a.m. Eastern Time*
- **UBS Obesity Therapeutics Day** (Virtual Conference)  
Thursday, May 23, 2024  
*Fireside Chat at 10:00 a.m. Eastern Time*

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

### About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow [@Altimune, Inc. on LinkedIn](#)

Follow [@AltimuneInc on Twitter](#)

### Company Contact:

Richard Eisenstadt  
Chief Financial Officer  
Phone: 240-654-1450  
[ir@altimmune.com](mailto:ir@altimmune.com)

### Investor Contact:

Lee Roth  
Burns McClellan  
Phone: 646-382-3403  
[lroth@burnsmc.com](mailto:lroth@burnsmc.com)  
Julia Weilman  
Burns McClellan  
Phone: 646-732-4443  
[jweilman@burnsmc.com](mailto:jweilman@burnsmc.com)

### Media Contact:

Danielle Cantey  
Inizio Evoke Comms  
Phone: 619-826-4657  
[Danielle.cantey@inizioevoke.com](mailto:Danielle.cantey@inizioevoke.com)



Source: Altimune, Inc